Chen, Jian-TingJian-TingChenHsu, Yuan-LingYuan-LingHsuHsu, Yi-ChiungYi-ChiungHsuTseng, Yi-HsinYi-HsinTsengLiu, Ming-HanMing-HanLiuWeng, Chia-WeiChia-WeiWengLin, Ching-HaoChing-HaoLinSZU-HUA PANChen, Jeremy J WJeremy J WChenWang, Chi-ChungChi-ChungWang2023-02-232023-02-2320222234-943Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85136962242&doi=10.3389%2ffonc.2022.801300&partnerID=40&md5=d7819191cd32c9f72f559f341cd3c64bhttps://scholars.lib.ntu.edu.tw/handle/123456789/628716Despite advances in prognosis and treatment of lung adenocarcinoma (LADC), a notable non-small cell lung cancer subtype, patient outcomes are still unsatisfactory. New insight on novel therapeutic strategies for LADC may be gained from a more comprehensive understanding of cancer progression mechanisms. Such strategies could reduce the mortality and morbidity of patients with LADC. In our previous study, we performed cDNA microarray screening and found an inverse relationship between inhibitor of DNA binding 2 (Id2) expression levels and the invasiveness of LADC cells.enFAK; inhibitor of DNA binding protein 2; lung adenocarcinoma; metastasis; twistjournal article10.3389/fonc.2022.801300359829512-s2.0-85136962242WOS:000860276600001https://api.elsevier.com/content/abstract/scopus_id/85136962242